Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.
Joseph S. Wozny, MPH
Advertisement
Articles by Joseph S. Wozny, MPH
Advertisement
Latest Updated Articles
Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing PatternsPublished: August 15th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD
4
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
5
